Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study.

What Was Tested

Researchers studied Copper (Supplement) in the context of hyperparathyroidism in this randomized controlled trial publication.

Benign prostatic hyperplasia (BPH) is the most common urologic disease among elderly men.

Who Took Part

By PubMed's age tags, the people studied were older adults, men only.

Patients were asked to fill the International Prostatic Symptom Score (IPSS) questionnaire before and after treatment.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

What Was Measured

The subject headings attached to it are Dietary Supplements, Hyperplasia, Solanum lycopersicum, Prostatic Hyperplasia, Quality of Life and Urinary Tract.

The authors tagged it with the keywords Benign prostate hyperplasia, Food supplement, Lower urinary tract symptoms, Olive polyphenols and Tomato.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in people with hyperparathyroidism.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Journal of translational medicine), a journal based in England.

More context: the Copper (Supplement) compound page, Hyperparathyroidism research.